老挝引入PCV13两年后疫苗适龄儿童及未接种婴儿的肺炎链球菌携带状况
该研究在老挝引入13价肺炎球菌结合疫苗(PCV13)前后开展两次横断面鼻咽携带调查,纳入5-8周龄婴儿(n=1000)和12-23月龄儿童(n=1010)。结果显示12-23月龄儿童PCV13型携带相对下降23%(aPR 0.77 [0.61-0.96]),非PCV13型无显著变化,未接种婴儿中趋势提示间接效应但无统计学意义。
要点
- 12-23月龄儿童PCV13型携带相对下降23%(aPR 0.77 [0.61-0.96])。
- 未接种婴儿PCV13型携带无显著变化(aPR 0.74 [0.43-1.27]),趋势提示间接效应。
- 超过70%肺炎球菌阳性样本含至少一种耐药基因,PCV13型更常见(p<0.001)。
核心结论
- 老挝引入PCV13两年后,疫苗适龄儿童PCV13型携带相对下降23%,可能减少肺炎球菌传播和疾病。
研究设计与样本
- 研究为两次横断面携带调查(PCV前和PCV后两年),纳入5-8周龄婴儿(n=1000)和12-23月龄儿童(n=1010)。
- 采用定量实时PCR检测肺炎球菌,DNA微阵列进行分子血清分型。
主要发现
- 12-23月龄儿童PCV13型携带相对下降23%(aPR 0.77 [0.61-0.96]),非PCV13型携带无显著变化(aPR 1.11 [0.89-1.38])。
- 未接种婴儿PCV13型携带无显著变化(aPR 0.74 [0.43-1.27]),非PCV13型无显著变化(aPR 1.29 [0.85-1.96]),趋势提示间接效应。
- 超过70%肺炎球菌阳性样本含至少一种耐药基因,PCV13型中更常见(p<0.001)。
- 在12-23月龄儿童中,PCV13接种者PCV13型和非PCV13型肺炎球菌密度均高于接种不足者(p=0.004和p<0.001)。
临床怎么用
- 在低收入亚洲地区引入PCV13后,应监测疫苗适龄儿童携带变化以评估间接效应。
- 未接种婴儿的携带趋势提示需关注群体免疫的延迟出现。
- 高耐药基因携带率提示在PCV13型中需结合 antimicrobial resistance 监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pneumococcal carriage is a prerequisite for disease, and underpins herd protection provided by pneumococcal conjugate vaccines (PCVs). There are few data on the impact of PCVs in lower income settings, particularly in Asia. In 2013, the Lao People's Democratic Republic (Lao PDR) introduced 13-valent PCV (PCV13) as a 3 + 0 schedule (doses at 6, 10 and 14 weeks of age) with limited catch-up vaccination. We conducted two cross-sectional carriage surveys (pre- and two years post-PCV) to assess the impact of PCV13 on nasopharyngeal pneumococcal carriage in 5-8 week old infants (n = 1000) and 12-23 month old children (n = 1010). Pneumococci were detected by quantitative real-time PCR, and molecular serotyping was performed using DNA microarray. Post PCV13, there was a 23% relative reduction in PCV13-type carriage in children aged 12-23 months (adjusted prevalence ratio [aPR] 0.77 [0.61-0.96]), and no significant change in non-PCV13 serotype carriage (aPR 1.11 [0.89-1.38]). In infants too young to be vaccinated, there was no significant change in carriage of PCV13 serotypes (aPR 0.74 [0.43-1.27]) or non-PCV13 serotypes (aPR 1.29 [0.85-1.96]), although trends were suggestive of indirect effects. Over 70% of pneumococcal-positive samples contained at least one antimicrobial resistance gene, which were more common in PCV13 serotypes (p < 0.001). In 12-23 month old children, pneumococcal density of both PCV13 serotypes and non-PCV13 serotypes was higher in PCV13-vaccinated compared with undervaccinated children (p = 0.004 and p < 0.001, respectively). This study provides evidence of PCV13 impact on carriage in a population without prior PCV7 utilisation, and provides important data from a lower-middle income setting in Asia. The reductions in PCV13 serotype carriage in vaccine-eligible children are likely to result in reductions in pneumococcal transmission and disease in Lao PDR.
引用
- Satzke C, Dunne EM, Choummanivong M, et al. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine. Vaccine. 2018. PMID: 30502068. doi:10.1016/j.vaccine.2018.10.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。